Treats spasticity. ANDA 76533, held by Apotex. Tizanidine Hydrochloride.
As of Nov 21, 2026, ANDA 76533 (Tizanidine Hydrochloride), held by Apotex, was first approved by FDA on Jan 16, 2004, with 5 approved supplements and 0 published complete response letters.
Tizanidine is indicated for the treatment of spasticity in adults. Tizanidine is a central alpha-2-adrenergic agonist indicated for the treatment of spasticity.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 16, 2004 | Original application | Approved | None posted |
| Tizanidine HydrochlorideEQ 2MG BASE · tablet;oral | Tizanidine Hydrochloride | Rx |
| Tizanidine HydrochlorideEQ 4MG BASE · tablet;oral | Tizanidine Hydrochloride | Rx |
| Mar 3, 2025 | Supplement 15Labeling · Standard review | Approved | None posted |
| Dec 17, 2024 | Supplement 13Labeling · Standard review | Approved | None posted |
| Sep 28, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 28, 2015 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 2, 2008 | Supplement 2Labeling | Approved | None posted |
| Jan 16, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters